- Home
- AUID vs IMAB Comparison
AUID vs IMAB Comparison
Compare AUID & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- IMAB
- Stock Information
- Founded
- AUID 2009
- IMAB 2014
- Country
- AUID United States
- IMAB United States
- Employees
- AUID N/A
- IMAB N/A
- Industry
- AUID Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- IMAB Health Care
- Exchange
- AUID Nasdaq
- IMAB Nasdaq
- Market Cap
- AUID 88.5M
- IMAB 83.8M
- IPO Year
- AUID N/A
- IMAB 2020
- Fundamental
- Price
- AUID $7.03
- IMAB $0.92
- Analyst Decision
- AUID
- IMAB Strong Buy
- Analyst Count
- AUID 0
- IMAB 3
- Target Price
- AUID N/A
- IMAB $8.00
- AVG Volume (30 Days)
- AUID 41.9K
- IMAB 452.7K
- Earning Date
- AUID 11-07-2024
- IMAB 08-28-2024
- Dividend Yield
- AUID N/A
- IMAB N/A
- EPS Growth
- AUID N/A
- IMAB N/A
- EPS
- AUID N/A
- IMAB N/A
- Revenue
- AUID $758,638.00
- IMAB $3,313,984.00
- Revenue This Year
- AUID N/A
- IMAB N/A
- Revenue Next Year
- AUID N/A
- IMAB N/A
- P/E Ratio
- AUID N/A
- IMAB N/A
- Revenue Growth
- AUID 97.40
- IMAB N/A
- 52 Week Low
- AUID $4.62
- IMAB $0.90
- 52 Week High
- AUID $13.63
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- AUID 57.74
- IMAB 38.53
- Support Level
- AUID $5.50
- IMAB $0.90
- Resistance Level
- AUID $6.37
- IMAB $0.98
- Average True Range (ATR)
- AUID 0.79
- IMAB 0.07
- MACD
- AUID 0.07
- IMAB -0.00
- Stochastic Oscillator
- AUID 100.00
- IMAB 10.00
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises "Know Who's Behind the Device" for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric passwordless authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).